Trispecific antibodies are the next frontier in targeted cancer therapy, offering a powerful new approach to treating complex diseases. These innovative antibodies are designed to bind to three different antigens simultaneously, enhancing treatment precision. By engaging multiple targets at once, trispecific antibodies can recruit immune cells, attack cancer cells, and block survival signals simultaneously, leading to more effective and comprehensive tumor elimination. This multi-targeted strategy not only boosts the immune response but also reduces the chances of cancer evading treatment.
What makes trispecific antibodies even more promising is their potential to ...
